Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (7521)	4/28/2005 12:05:33 PM
From: rrufff	Read Replies (1) \| Respond to of 23958

IMX 4.80 + 46. String of good days unseen in a long time, possible major trend reversal. Let's see if it breaks $5. Fundamentally, very little value is being given to the explosive detection division, which is the wild card and potential excitement.

To: Sergio H who wrote (7521)	5/10/2005 8:25:50 AM
From: rrufff	Read Replies (1) \| Respond to of 23958

IMX - Implant Sciences Receives Order for Explosives Detection Equipment from Republic of Korea; Quantum Sniffers Explosives Detection Equipment to Be Used for Protection of High Level Government Building Business Wire - May 10, 2005 08:11 WAKEFIELD, Mass., May 10, 2005 (BUSINESS WIRE) -- Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced the receipt of an order for three (3) units of its Quantum Sniffer handheld explosives detection equipment (the "QS-H100") from the Republic of Korea. It is our understanding that the QS-H100 will be used for the protection of a high level government building. The QS-H100 was developed for use in the detection of trace residues of explosives materials for aviation and transportation security, protection of high threat facilities, infrastructure, customs and border protection, and cargo screening. Government officials invited Implant's sales engineer and exclusive sales representative to South Korea to perform a comprehensive demonstration of our QS-H100 equipment. The QS-H100 is a mobile, handheld device that detects the presence of explosive vapors in real time without the need to physically contact the articles under examination. During the course of our demonstration, the QS-H100 satisfactorily met the South Korean government requirements and specifications which lead to the successful award of this order. Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, commented, "We are encouraged by our success in meeting the South Korean requirements for explosives detection and the positive reception to our equipment by the officials of the Republic of Korea. We believe the current planned installation of our QS-H100 trace explosives detection equipment in this important high level South Korean government building should provide the Company a high level of visibility that could support our efforts to bid on any future installations of explosives trace detection equipment in South Korea." About Implant Sciences Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top trace element detection devices to identify explosives. In addition, to its other cancer treatment products the Company recently received an FDA 510k approval for its new radioactive source for the use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com. Implant Sciences believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission. SOURCE: Implant Sciences Aurelius Consulting Group: Dave Gentry/Jeff Wadley, 407-644-4256 dave@aurcg.com www.runonideas.com or Implant Sciences Corporation: David C. Volpe, 508-523-3141 dvolpe@implantsciences.com www.implantsciences.com Copyright Business Wire 2005